miR‑491‑3p functions as a tumor suppressor in non‑small cell lung cancer by targeting fibroblast growth factor 5

Zhang,Gai; Zheng,Haijian; Wang,Ling

doi:10.3892/or.2022.8379

miR‑491‑3p functions as a tumor suppressor in non‑small cell lung cancer by targeting fibroblast growth factor 5

Authors:
- Gai Zhang
- Haijian Zheng
- Ling Wang
View Affiliations

Affiliations: Department of General Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: July 22, 2022 https://doi.org/10.3892/or.2022.8379
Article Number: 164
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to identify the function of miR‑491‑3p in regulating non‑small cell lung cancer (NSCLC). Tumor tissues and adjacent normal tissues were collected from 43 patients with NSCLC. A549 and H1299 cells were transfected with microRNA (miR)‑491‑3p mimic, mimic negative control (NC), miR‑491‑3p inhibitor, inhibitor NC, pcDNA3.1‑FGF5 vector and control vector. Cell counting kit‑8 assay and Edu experiments were performed to assess cell viability and proliferation. Matrigel experiment, wound healing assay and flow cytometric analysis were performed to explore cell invasion, migration and apoptosis, respectively. A dual‑luciferase reporter experiment was performed to identify the relationship between miR‑491‑3p and fibroblast growth factor 5 (FGF5). In vivo study was conducted by using nude mice. The miR‑491‑3p and FGF5 protein expression levels were investigated using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. In NSCLC tumor tissues, miR‑491‑3p was downregulated and FGF5 was upregulated (P<0.01). Low miR‑491‑3p expression and high FGF5 mRNA expression was associated with poor outcomes in patients, including advanced TNM stage and lymph node metastasis (P<0.05). upregulation of miR‑491‑3p suppressed viability, proliferation, invasion and migration of NSCLC cells; however, it promoted apoptosis (P<0.01). FGF5 was a target gene for miR‑491‑3p. miR‑491‑3p directly inhibited FGF5 expression. upregulation of FGF5 significantly reversed the inhibitory effects of miR‑491‑3p on malignant phenotypes of NSCLC cells (P<0.01). miR‑491‑3p overexpression suppressed the in vivo growth of NSCLC. Thus, it was identified that miR‑491‑3p functions as a tumor suppressor in NSCLC by directly targeting FGF5.

View Figures

View References

1	Khanmohammadi A, Aghaie A, Vahedi E, Qazvini A, Ghanei M, Afkhami A, Hajian A and Bagheri H: Electrochemical biosensors for the detection of lung cancer biomarkers: A review. Talanta. 206:1202512020. View Article : Google Scholar
2	Yu Q, Xu L, Chen L, Sun B and Yang Z, Lu K and Yang Z: Vinculin expression in non-small cell lung cancer. J Int Med Res. 48:3000605198395232020. View Article : Google Scholar : PubMed/NCBI
3	Gelatti AC, Drilon A and Santini FC: Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 137:113–122. 2019. View Article : Google Scholar : PubMed/NCBI
4	Brozos-Vázquez EM, Díaz-Peña R, García-González J, León-Mateos L, Mondelo-Macía P, Peña-Chilet M and López-López R: Immunotherapy in nonsmall-cell lung cancer: Current status and future prospects for liquid biopsy. Cancer Immunol Immunother. 70:1177–1188. 2021. View Article : Google Scholar
5	Alexander M, Kim SY and Cheng H: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020. View Article : Google Scholar : PubMed/NCBI
6	Chen X, Zhao L, Kang Y, He Z, Xiong F, Ling X and Wu J: Significant suppression of non-small-cell lung cancer by hydrophobic poly(ester amide) nanoparticles with high docetaxel loading. Front Pharmacol. 9:1182018. View Article : Google Scholar
7	Zhong W, Zhang X, Zeng Y, Lin D and Wu J: Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 14:2067–2089. 2021. View Article : Google Scholar : PubMed/NCBI
8	Xiong F, Ling X, Chen X, Chen J, Tan J, Cao W, Ge L, Ma M and Wu J: Pursuing specific chemotherapy of orthotopic breast cancer with lung metastasis from docking nanoparticles driven by bioinspired exosomes. Nano Lett. 19:3256–3266. 2019. View Article : Google Scholar
9	Naeli P, Yousefi F, Ghasemi Y, Savardashtaki A and Mirzaei H: The role of MicroRNAs in lung cancer: Implications for diagnosis and therapy. Curr Mol Med. 20:90–101. 2020. View Article : Google Scholar : PubMed/NCBI
10	Grossi I, Salvi A, Abeni E, Marchina E and De Petro G: Biological function of microRNA193a-3p in health and disease. Int J Genomics. 2017:59131952017. View Article : Google Scholar : PubMed/NCBI
11	Shan C, Chen X, Cai H, Hao X, Li J, Zhang Y, Gao J, Zhou Z, Li X, Liu C, et al: The emerging roles of autophagy-related MicroRNAs in cancer. Int J Biol Sci. 17:134–150. 2021. View Article : Google Scholar
12	Hu Y, Zhao M, Li L, Ding J, Gui YM and Wei TW: miR-491-3p is downregulated in retinoblastoma and inhibit tumor cells growth and metastasis by targeting SNN. Biochem Genet. 59:453–474. 2021. View Article : Google Scholar
13	Duan J, Liu J, Liu Y, Huang B and Rao L: miR-491-3p suppresses the growth and invasion of osteosarcoma cells by targeting TSPAN1. Mol Med Rep. 16:5568–5574. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zhao Y, Qi X, Chen J, Wei W, Yu C, Yan H, Pu M, Li Y, Miao L, Li C and Ren J: The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett. 408:102–111. 2017. View Article : Google Scholar
15	Zheng G, Jia X, Peng C, Deng Y, Yin J, Zhang Z, Li N, Deng M, Liu X, Liu H, et al: The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. Oncotarget. 6:6931–6943. 2015. View Article : Google Scholar
16	Wang X, He Y, Mackowiak B and Gao B: MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 70:784–795. 2021. View Article : Google Scholar
17	Zhou Y, Yu Q, Chu Y, Zhu X, Deng J, Liu Q and Wang Q: Downregulation of fibroblast growth factor 5 inhibits cell growth and invasion of human nonsmall-cell lung cancer cells. J Cell Biochem. Dec 5–2018.(Epub ahead of print). doi: 10.1002/jcb.28107.
18	Zhao T, Qian K and Zhang Y: High expression of FGF5 is an independent prognostic factor for poor overall survival and relapse-free survival in lung adenocarcinoma. J Comput Biol. 27:948–957. 2020. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Liang G, Meng W, Huang X, Zhu W, Yin C, Wang C, Fassan M, Yu Y, Kudo M, Xiao S, et al: miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer. Proc Natl Acad Sci USA. 117:4347–4357. 2020. View Article : Google Scholar : PubMed/NCBI
21	Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C and Foti M: Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar
22	Liao Y, Cao L, Wang F and Pang R: miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer. J Cell Biochem. 121:779–787. 2020. View Article : Google Scholar : PubMed/NCBI
23	Wang Z, Zhu X, Zhang T and Yao F: miR-512-5p suppresses the progression of non-small cell lung cancer by targeting β-catenin. Oncol Lett. 19:415–423. 2020.
24	Jiang Z, Zhang J, Chen F and Sun Y: miR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway. Thorac Cancer. 11:415–425. 2020. View Article : Google Scholar : PubMed/NCBI
25	Pu JT, Hu Z, Zhang DG, Zhang T, He KM and Dai TY: miR-654-3p suppresses non-small cell lung cancer tumourigenesis by inhibiting PLK4. Onco Targets Ther. 13:7997–8008. 2020. View Article : Google Scholar : PubMed/NCBI
26	Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
27	Kehler JS, David VA, Schäffer AA, Bajema K, Eizirik E, Ryugo DK, Hannah SS, O'Brien SJ and Menotti-Raymond M: Four independent mutations in the feline fibroblast growth factor 5 gene determine the long-haired phenotype in domestic cats. J Hered. 98:555–566. 2007. View Article : Google Scholar : PubMed/NCBI
28	Huang Y, Wang Y and Yang Y: Expression of fibroblast growth factor 5 (FGF5) and its influence on survival of breast cancer patients. Med Sci Monit. 24:3524–3530. 2018. View Article : Google Scholar
29	Han D, Wang M, Yu Z, Yin L, Liu C, Wang J, Liu Y, Jiang S, Ren Z and Yin J: FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway. Cancer Manag Res. 11:6457–6466. 2019. View Article : Google Scholar : PubMed/NCBI
30	Liu D, Zhang C, Li X, Zhang H, Pang Q and Wan A: MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma. EXCLI J. 17:102–112. 2018.PubMed/NCBI
31	Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar
32	Kornmann M, Ishiwata T, Beger HG and Korc M: Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions. Oncogene. 15:1417–1424. 1997. View Article : Google Scholar : PubMed/NCBI